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Introduction
Malaria is one of the leading causes of morbidity in endemic 
countries. Between 350 and 660 million clinical episodes 
of the disease occur per year among African children,1,2 and 
roughly 1.2 million deaths (representing 2% of all premature 
deaths in the world) are caused annually by malaria in low- 
and middle-income countries,3 although estimates range from 
700 000 to 2.7 million deaths per year.4 Of all global deaths 
due to malaria, around 75% are estimated to occur in African 
children.4
Current WHO recommendations for malaria control in 
children in endemic areas rely on case management, use of 
insecticide-treated nets and vector control,5,6 none of which 
has proved fully efficacious for controlling the infection.7–11 
Hence, there is a need to test new strategies that, combined 
with existing interventions, can effectively reduce the burden 
of malaria among children in endemic areas.5
The delivery of intermittent preventive treatment in 
infants (IPTi) during routine contacts through the Expanded 
Programme on Immunization (EPI)12–14 is a promising ma-
laria control strategy whose efficacy rates in the prevention 
of malaria episodes15–21 range from 22.6%16 to 63.2%.18 
Objective To estimate the cost-effectiveness of malaria intermittent preventive treatment in infants (IPTi) using sulfadoxine-
pyrimethamine (SP).
Methods In two previous IPTi trials in Ifakara (United Republic of Tanzania) and Manhiça (Mozambique), SP was administered three 
times to infants before 9 months of age through the Expanded Programme on Immunization. Based on the efficacy results of the 
intervention and on malaria incidence in the target population, an estimate was made of the number of clinical malaria episodes 
prevented. This number and an assumed case-fatality rate of 1.57% were used, in turn, to estimate the number of disability-adjusted 
life years (DALY) averted and the number of deaths averted. The cost of the intervention, including start-up and recurrent costs, was 
then assessed on the basis of these figures.
Findings The cost per clinical episode of malaria averted was US$ 1.57 (range: US$ 0.8–4.0) in Ifakara and US$ 4.73 (range: 
US$ 1.7–30.3) in Manhiça; the cost per DALY averted was US$ 3.7 (range: US$ 1.6–12.2) in Ifakara and US$ 11.2 (range: US$ 
3.6–92.0) in Manhiça; and the cost per death averted was US$ 100.2 (range: US$ 43.0–330.9) in Ifakara and US$ 301.1 (range: 
US$ 95.6–2498.4) in Manhiça.
Conclusion From the health system and societal perspectives, IPTi with SP is expected to produce health improvements in a cost-
effective way. From an economic perspective, it offers good value for money for public health programmes.
Une traduction en français de ce résumé figure à la fin de l’article. Al final del artículo se facilita una traducción al español.
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Cost-effectiveness analysis, which provides information that 
is crucial for policy recommendations for malaria control at 
both the national and international levels, can help guide the 
optimal allocation of health sector resources.22,23 To provide 
this information, we carried out a cost-effectiveness analysis 
based on the results of two very similar IPTi trials, one of 
which was undertaken in Ifakara, the United Republic of 
Tanzania, and the other in Manhiça, Mozambique.16,18
Methods
Study area and population
The trials are described in more detail elsewhere.16,18 The Tanza-
nian trial was based in Ifakara town (Kilombero district), whose 
population is 55 000. Malaria transmission is perennial, with 
two rainy seasons and a cool dry season from July to September. 
Sulfadoxine-pyrimethamine (SP) was the recommended first-
line treatment for malaria during the study. Compliance with 
the routine EPI vaccination schedule was high, with 92% of 
children receiving three doses of diphtheria–tetanus–pertussis 
(DTP) vaccine plus oral poliovirus vaccine and 80% receiv-
ing measles vaccine. The rate of use of insecticide-treated nets 
was 70%.
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The Mozambican study was based 
in Manhiça (Maputo province), a town 
of 36 000 inhabitants in southern Mo-
zambique with a subtropical climate, a 
warm rainy season from November to 
April, and a cool, dry season the rest 
of the year. Compliance with EPI vac-
cines is very high, as more than 95% 
of children receive all three doses of 
the combination vaccine against DTP, 
polio and hepatitis B, and more than 
85% are vaccinated against measles. 
In both sites malaria transmission is 
mostly due to Plasmodium falciparum. 
Insecticide-treated nets are not used in 
the community.
Cost-effectiveness analysis
The cost-effectiveness analysis presented 
here follows standard cost-effectiveness 
methods.24–28 In cost-effectiveness analy-
sis, the costs and outcomes of a new 
health intervention are compared with 
those of the currently practiced inter-
ventions and/or with doing nothing (no 
intervention). This enables the selection 
of competing interventions, based on 
their relative efficiency, to obtain better 
value for money in health spending and 
other benefits. To estimate the cost-
effectiveness ratios of the IPTi interven-
tion, the estimated aggregate effect of 
the IPTi intervention was divided by 
the estimated aggregate cost of providing 
the intervention for a reference target 
population of 1000 immunized infants. 
The cost-effectiveness ratios presented are 
incremental and reflect a comparison of 
the IPTi intervention with a do-nothing 
alternative. They include the cost per 
malaria episode averted, the cost per 
disability-adjusted life year (DALY) 
averted,29–32 and the cost per malaria 
death averted. DALYs averted were calcu-
lated by combining the burden of disease 
averted due to less malaria morbidity (as 
a function of malaria incidence, disease 
duration and impact on quality of life) 
and less malaria mortality (as a function 
of malaria incidence, case-fatality rate 
and average life expectancy at age 1 year). 
Cost-effectiveness ratios are presented 
in United States dollars (US$) for the 
year 2006.
Estimation of health impact
The IPTi intervention evaluated in this 
analysis included the delivery of single 
doses of SP up to three times during the 
first year of life, alongside routine EPI 
vaccinations.
The health effects used in the cost-
effectiveness analysis were based on the 
efficacy results from the Ifakara and 
Manhiça trials and on the incidence 
of malaria in these sites at the time of 
the trials.16,18 For the purposes of the 
economic evaluation, we used the total 
number of cases averted for a reference 
population of 1000 infants, based 
on the number of children enrolled 
in the trials who had received at least 
one dose of SP by 12 months of age. 
The trial results showed a reduction in 
the incidence of all malaria episodes of 
63.2% (95% confidence interval, CI: 
44.2–74.6) in Ifakara18 and 22.2% (95% 
CI: 3.9–37.0) in Manhiça.16 Neither 
study showed an increase in clinical epi-
sodes of malaria after discontinuation 
of IPTi (rebound effect).16,33 The ma-
laria attack rates in the placebo group 
were 35.2% and 40.2% in the Ifakara 
and Manhiça trials, respectively. The 
cost-effectiveness ratio was also calcu-
lated using the pooled efficacy of the six 
completed IPTi trials that compared SP 
with placebo, which has been estimated 
at 30.1% (range: 19.7–39.1) against all 
clinical malaria episodes.34
Fewer malaria cases mean fewer 
malaria deaths. None of the IPTi trials 
conducted to date has been large enough 
to provide a direct estimate of the ef-
fect of the intervention on mortality. 
However, previous studies have shown 
that reducing malaria incidence does 
reduce mortality from the disease.35 
Case-fatality field data derived from 
hospital admissions only have revealed 
case-fatality rates (CFRs) for malaria in 
infants ranging from 4.7%36 to 5.8%.37 
A recent epidemiological model based 
on field data yielded a case-fatality rate 
for malaria in infants of 1.57%,38,39 
and that is the rate we employed in 
this study. Because hospitalized infants 
are more likely to have severe malaria 
episodes, it was considered more ap-
propriate to use the lower rate of 1.57% 
to reflect the CFR for clinical episodes 
of all types. DALYs were calculated ac-
cording to standard methods, excluding 
age weighting.40–42 For infant deaths, an 
average life expectancy of 51.35 years 
was used based on life tables for men 
and women in eastern Africa.43
Intervention costs
We calculated both the financial (bud-
getary) and the non-financial costs of the 
IPTi intervention, which together com-
prised its economic costs. Non-financial 
implications (opportunity costs) for 
resource use had to do, for instance, 
with the utilization of spare health sys-
tem capacity or the switching of health 
resources from one use to another.
To calculate economic costs of the 
IPTi intervention, we took into account 
all costs involved in implementing it, 
including the costs of planning, deliv-
ery and monitoring. We also included 
all costs associated with policy change 
(strategy definition), sensitization (meet-
ings with health sector stakeholders and 
district level health managers), behav-
iour change (communication to the 
population, staff training, intervention 
monitoring), the IPTi drug SP (import, 
purchase, storage and distribution), 
and drug administration (drug delivery, 
mothers’ education, and filling out the 
health card).
Intervention costs were partially 
collected from the two trials. However, 
as the conditions surrounding neither 
trial reflected actual practice in terms 
of IPTi delivery and costs incurred, 
intervention costs were taken instead 
from a more recent cost study that was 
part of an IPTi community effectiveness 
trial conducted from 2005 to 2008 in 
the southern United Republic of Tanza-
nia (Mtwara and Lindi regions), where 
Ifakara is also situated.44 The cost data 
collected from the Mwara and Lindi 
regions exclude research and other costs 
that are usually involved in clinical trials. 
Hence, they reflect the real costs of IPTi 
delivery in routine clinical practice in 
the southern part of the country. Given 
the similarities between Mozambique 
and the United Republic of Tanzania 
in per capita incomes and health ser-
vice delivery, including EPI schedule, 
the cost data collected in Mtwara and 
Lindi regions were also considered the 
most appropriate for application in the 
Manhiça study.44 Only the price of SP 
was treated as different between the 
two sites.
IPTi intervention costs are pre-
sented in Table 1, with financial and 
non-financial costs presented sepa-
rately. In the United Republic of 
Tanzania, the cost per dose of IPTi 
delivered was roughly US$ 0.128. Of 
this amount, 60% comprised financial 
costs: US$ 0.0536 per dose for training, 
US$ 0.019 per dose for sensitization, 
and US$ 0.0136 per dose for purchase 
of the drug (including wastage). An 
average dose of half a tablet of SP and 
an assumed wastage rate of 30% were 
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used to calculate the cost per dose, 
based on the price of the drug in 2006 
in the Medical Stores Department (the 
agency responsible for bulk purchases 
of medicines and medical supplies) 
of the United Republic of Tanzania. 
In Mozambique the drug price used 
was US$ 0.0375 per dose, and as a 
result the total cost per dose deliv-
ered (US$ 0.1522) was higher in that 
country. As not all infants receiving the 
first dose receive the second and third 
doses, the IPTi intervention costs for 
the reference target of 1000 infants 
were adjusted for a drop-out rate of 4% 
from the first to the second dose in both 
sites, and of 19% and 15% from the 
second to the third dose for Ifakara and 
Manhiça, respectively. Hence, 77% of 
infants in Ifakara and 81% in Manhiça 
were presumed to receive three doses 
of SP.16,18
Sensitivity analysis
Multivariate sensitivity analysis was per-
formed using Monte-Carlo simulations 
generated by @Risk (version 4.5) add-
in tool to Microsoft Excel© (Palisade 
Corporation, Ithaca, NY, USA) to 
explore the robustness of the results in 
the face of simultaneous variation in 
selected assumptions and data inputs. 
Cost-effectiveness ranges were gener-
ated stochastically by varying four key 
input parameters – IPTi efficacy, case-
fatality rate, malaria attack rate and cost 
per dose of IPTi delivered – in 10 000 
simulations. The efficacy ranges were 
defined by the 95% CI from the trials 
themselves, while for the other three 
variables the 95% confidence ranges 
were assumed. The range distributions 
were assumed to be triangular.
Table 1.  Intervention costs per dose of SP delivered in Mozambique (Manhiça) and the 
United Republic of Tanzania (Ifakara) (2006 prices)
Activity component Health 
system 
level
Financial 
costs 
(US$ cents)
Opportunity 
costs 
(US$ cents)
Total costs 
(US$ cents)
Planning and management of 
strategy change
National 0.01 0.02 0.03
Sensitization District 0.76 1.12 1.88
Behaviour change communication National 0.03 00.05 0.08
Drug distribution National 1.50 0.00 1.50
Training District 3.06 2.30 5.36
Administration of intervention in 
health facilities
District 0.00 1.25 1.25
Strategy management National 0.65 0.10 0.75
District 0.62 0.00 0.62
Drug purchase (United Republic of 
Tanzania only)
National 1.10 0.26 1.36
Drug purchase (Mozambique only) National 3.49 0.26 3.75
Total (United Republic of Tanzania) National 3.29 0.43 3.72
District 4.44 4.67 9.11
Overall 7.73 5.10 12.83
Total (Mozambique) National 5.68 0.43 6.11
District 4.44 4.67 9.11
Overall 10.12 5.10 15.22
IPTi, intermittent preventive treatment in infants; SP, sulfadoxine-pyrimethamine. 
Source: Ref. 44.
Table 2.  Intervention costs, intervention efficacy and health benefits per 1000 infants 
receiving IPTi against malaria in Mozambique (Manhiça) and the United 
Republic of Tanzania (Ifakara), 2006
Intervention effects Ifakara Manhiça
Intervention costs (US$)a 350 422
IPTi efficacy (% and 95% CI) a,b 63.2 (44.2–74.6) 22.2 (3.9–37.0)
Malaria episodes averted 222.7 89.2
DALYs averted 118.9 47.6
Malaria deaths averted 3.5 1.4
CI, confidence interval; DALY, disability-adjusted life year; ITPi, intermittent preventive treatment in infants.
a  Sources: Intervention costs, ref. 44; IPTi efficacy, ref. 34.
b  Percentage reduction in malaria episodes.
Results
Table 2 shows health benefits and net 
intervention costs. Based on efficacy 
results from the two trial settings, the 
IPTi intervention resulted in 223 and 89 
prevented episodes of malaria in Ifakara 
and in Manhiça, respectively, for every 
1000 immunized infants. Assuming a 
case-fatality rate of 1.57%, the number 
of deaths averted per 1000 infants receiv-
ing the intervention was estimated at 
3.5 in Ifakara and 1.4 in Manhiça. The 
number of DALYs averted was estimated 
at 118.9 per 1000 infants in Ifakara and 
47.6 per 1000 infants in Manhiça. Inter-
vention costs were estimated at US$ 422 
per 1000 immunized infants in Manhiça 
and US$ 350 in Ifakara.
Cost-effectiveness ratios are present-
ed in Table 3. Using efficacy data from 
the two trial sites, the costs estimated 
were as follows: per DALY averted, 
US$ 3.7 (range: 1.6–12.2) for Ifakara 
and US$ 11.2 (range: 3.6–92.0) for 
Manhiça; per malaria episode averted, 
US$ 1.6 (range: 0.8–4.0) for Ifakara and 
US$ 4.7 (range: 1.7–30.3) for Man-
hiça; and per death averted, US$ 100.2 
(range: 43.0–330.9) for Ifakara and 
US$ 301.1 (range: 95.6–2498.4) for 
Manhiça.
Table 3 also presents cost-effective-
ness ratios using an efficacy rate of 30% 
from the pooled analysis including 
the six IPTi trials with SP.34 The costs 
estimated were as follows: per DALY 
averted, US$ 7.9 (range: 3.2–27.0) for 
Ifakara and US$ 8.3 (range: 3.3–27.5) 
for Manhiça; per malaria episode 
averted, US$ 3.3 (range: 1.4–10.3) 
for Ifakara and US$ 3.5 (range: 1.6–
11.0) for Manhiça; per death averted, 
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Table 3. Cost-effectiveness of malaria IPTi in a study in Mozambique (Manhiça)  and 
the United Republic of Tanzania (Ifakara), 2006
Cost-effectiveness ratiosa and ranges from 
Monte-Carlo simulation
Ifakara Manhiça
Using individual efficacy results
Cost per DALY averted 3.7 (1.6–12.2) 11.2 (3.6–92.0)
Cost per malaria episode averted 1.6 (0.8–4.0) 4.7 (1.7–30.3)
Cost per malaria death averted 100.2 (43.0–330.9) 301.1 (95.6–2498.4)
Using pooled efficacy results
Cost per DALY averted 7.9 (3.2–27.0) 8.3 (3.3–27.5)
Cost per malaria episode averted 3.3 (1.4–10.3) 3.5 (1.6–11.0)
Cost per malaria death averted 211.0 (84.5–730.2) 222.8 (88.6–747.1)
DALY, disability-adjusted life year; ITPi, intermittent preventive treatment in infants.
a  Ratios represent the estimated aggregate effect of the IPTi intervention divided by the estimated 
aggregate cost (US$) of providing the intervention for a reference target population of 1000 immunized 
infants. The cost portion of the cost-effectiveness ratio includes only intervention costs; cost savings from 
fewer malaria cases are excluded.
Table 4.  Distribution of probability parameters in probabilistic sensitivity analysis 
from study of malaria IPTi, Mozambique (Manhiça) and the United Republic of 
Tanzania (Ifakara), 2006
Probability input 
variable 
Type of 
probability 
distribution
Low 
estimate
Best 
estimate
High 
estimate
Source
IPTi efficacy
Manhiça Triangular 0.039 0.22 0.370 16
Ifakara Triangular 0.442 0.632 0.746 18
Pooled Triangular 0.197 0.300 0.390 34
Case fatality rate Triangular 0.010 0.0157 0.030 36,37
Malaria attack rate
Manhiça Triangular 0.202 0.400 0.599 16
Ifakara Triangular 0.182 0.353 0.528 18
Intervention costs 
per dose of SP (US$)
Manhiça Triangular 0.1065 0.1522 0.1979 44
Ifakara Triangular 0.0898 0.1283 0.1668 44
ITPi, intermittent preventive treatment in infants; SP, sulfadoxine-pyrimethamine.
US$ 211.0 (range: 84.5–730.2) for 
Ifakara and US$ 222.8 (range: 88.6–
747.1) for Manhiça.
Discussion
According to the cost-effectiveness 
analysis of IPTi, this strategy could be 
classified as highly cost-effective for 
controlling malaria in African infants. 
The cost per DALY averted was under 
US$ 12, and the cost per death averted 
was under US$ 310 in both study sites. 
Due to the higher efficacy reported in 
the Ifakara trial, cost-effectiveness ra-
tios were more favourable in that study 
than in the one conducted in Manhiça. 
However, the reverse results were ob-
tained when the pooled efficacy results 
were used.
IPTi offers an excellent value for 
the money when judged by a standard 
of under US$ 50 per DALY averted for 
a “very cost-effective intervention”.22 
There are two further benefits of the 
IPTi intervention that are not reflected 
in these findings: anaemia prevention 
and cost savings. In past trials, the IPTi 
intervention (using SP) has been shown 
to reduce the incidence of anaemia by as 
much as 15.1% (95% CI: 6.3–23.1)34. 
Furthermore, the fewer the cases of 
malaria, the less treatment-seeking 
and the greater the cost savings, a fact 
not reflected in the cost-effectiveness 
ratios presented above. While care is 
not sought for all malaria cases, most 
receive some form of therapy, either in 
a public or private clinic, a traditional 
care setting, or as self-treatment. These 
additional cost savings to the health 
system make the intervention even 
more attractive for ministries of health 
of malaria-endemic countries. When 
savings to the patient are considered (in 
health-care costs, transportation costs, 
travel time and time spent ill, etc.), the 
intervention becomes more attractive 
for its beneficiaries as well.
This study is beset by several un-
certainties. The multivariate sensitivity 
analysis yielded wide confidence inter-
vals resulting from the ranges of four 
key input parameters. For example, 
the cost per DALY averted ranged from 
US$ 1.6 to US$ 12.2 in the United Re-
public of Tanzania and from US$ 3.6 
to US$ 92.0 in Mozambique. However, 
these wide ranges were generated because 
a considerable degree of uncertainty in 
the selected parameters was allowed 
for, as shown in Table 4. Furthermore, 
even with an upper confidence limit 
of US$ 12.2 per DALY averted in the 
United Republic of Tanzania and an 
upper confidence limit of US$ 92.0 per 
DALY averted in Mozambique, IPTi is 
still an attractive health intervention. 
Counting only the financial cost of 
the IPTi intervention in Mozambique 
would reduce the upper confidence 
limit for the cost per DALY averted to 
US$ 61.
A key uncertain variable – the case-
fatality rate among infants – accounts 
for a significant share of the DALYs 
averted associated with malaria control 
interventions. For the multivariate 
analysis, a lower case-fatality rate of 
1% was assumed If the case-fatality 
rate were in fact zero, the cost per 
DALY averted would be considerably 
higher at US$ 157.3 in the United 
Republic of Tanzania and US$ 472.7 
in Mozambique. However, excluding 
such a potential health benefit from 
the cost-effectiveness calculation would 
underestimate the cost-effectiveness of 
the IPTi intervention, since in Africa 
malaria causes a considerable number of 
deaths in the target population of chil-
dren less than 2 years of age. Further-
more, if mortality impact were excluded 
from this analysis, it would also need 
to be excluded from the evaluation 
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of other malaria control interventions 
(see below).
Compared with other malaria 
control interventions targeting young 
children in Africa, IPTi appears to be 
among the most cost-effective. For 
example, a previous study reported a 
cost of US$ 10.3 per DALY averted for 
SP delivered weekly to infants between 
2 and 12 months of age.36 A recent 
African continent-wide cost-effec-
tiveness analysis using secondary data 
sources reported the following costs 
per DALY averted: case management 
with artemisinin-based combination 
therapy, US$ 10–12; insecticide-treated 
nets, US$ 29–40; and indoor residual 
spraying, US$ 32–41.45 In a review of 
malaria prevention strategies in child-
hood, the cost per DALY averted using 
insecticide-treated nets was found to 
be above US$ 9, including cost sav-
ings.23 Thus IPTi, at a cost of less than 
US$ 12 per DALY averted and with 
the likelihood of additional cost sav-
ings to the health system and patient, 
is found to be at least as cost-effective 
as other options for malaria control 
among infants.
From the health and cost-benefit 
points of view, IPTi merits serious 
consideration by health policy-makers, 
as it can have a major health impact in 
a vulnerable population, irrespective of 
the mortality impact of the interven-
tion. Even if only the IPTi intervention 
costs are considered and potential cost 
savings are excluded, cost-effectiveness 
ratios are highly favourable and good 
value for money.
The Intermittent Preventive Treat-
ment in Infants Consortium identified 
several issues, in addition to safety, effi-
cacy and potential interactions between 
IPTi and EPI vaccines, which have been 
included in a portfolio of research to 
evaluate the potential of incorporating 
IPTi into malaria control strategies. Ac-
ceptability, immunological effects and 
impact on drug resistance are currently 
being investigated, although published 
models provide reassurance that IPTi 
is unlikely to have a dramatic effect on 
the spread of drug resistance.46,47
The difference between IPTi and 
intermittent preventive therapy in preg-
nancy (IPTp) should be understood by 
policy-makers, as these interventions do 
not directly compete with each other. 
While IPTi targets infants mainly to 
reduce malaria and anaemia among 
them, IPTp targets both mothers and 
infants and entails a broader set of 
health benefits for the infant, among 
them improved birth weight and fetal 
development, which result in significant 
long-term developmental gains. Hence, 
these strategies should, if possible, be 
implemented in parallel to attain opti-
mal health benefits in these vulnerable 
populations.
In conclusion, the cost-effectiveness 
ratios of IPTi with SP are highly favour-
able in the two settings included in this 
study. These findings are likely to hold 
for other settings where IPTi is imple-
mented provided a single-drug regimen 
is used for IPTi through the routine 
EPI schedule and malaria attack rates, 
IPTi efficacy rates and intervention 
costs resemble those evaluated in this 
study. Based on the cost-effectiveness 
of the intervention, it is recommended 
that IPTi with SP be implemented 
in malaria-endemic countries in sub-
Saharan Africa as soon as possible, while 
ensuring that the intervention reaches 
the maximum number of infants 
through a routine contact point in the 
health system.  ■
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Résumé
Rapport coût/efficacité du traitement préventif intermittent contre le paludisme (TPI) chez le nourrisson au 
Mozambique et en République unie de Tanzanie
Objectif Estimer le rapport coût/efficacité d’un traitement préventif 
intermittent contre le paludisme (TPI) à base de sulfadoxine-
pyriméthamine (SP) chez le nourrisson.
Méthodes Dans le cadre de deux essais antérieurs du TPI menés à 
Ifakara (République unie de Tanzanie) et à Manhiça (Mozambique), 
de la SP a été administrée à trois reprises à des nourrissons avant 
qu’ils atteignent 9 mois, par le biais du Programme élargi de 
vaccination. A partir des résultats d’efficacité de l’intervention et 
de l’incidence du paludisme dans la population cible, on a établi 
une estimation du nombre d’épisodes de paludisme clinique évités. 
On a utilisé à son tour ce nombre et un taux de létalité supposé 
de 1,57 % pour estimer le nombre d’années de vie corrigées de 
l’incapacité (DALY) et le nombre de décès évités. Sur la base de ces 
chiffres, on a ensuite évalué le coût de l’intervention (y compris les 
coûts de lancement et les coûts récurrents).
Résultats Le coût par épisode de paludisme clinique évité se 
montait à US $ 1,57 (plage de variation : US $ 0,8-4,0) à Ifakara et 
à US $ 4,73 (plage de variation : US $ 1,7-30,3) à Manhiça ; le coût 
par DALY évitée était de US $ 3,7 (plage de variation : US $ 1,6-
12,2) à Ifakara et de US $ 11,2 (plage de variation : US $ 3,6-92,0) 
à Manhiça ; et le coût par décès évité atteignait US $ 100,2 (plage 
de variation : US $ 43,0-330,9) à Ifakara et US $ 301,1 (plage de 
variation : US $ 95,6-2498,4) à Manhiça.
Conclusion Du point de vue du système de santé et de la société, 
on s’attend à ce qu’un TPI à base de SP apporte des améliorations 
sur le plan sanitaire avec un bon rapport coût/efficacité. Dans une 
perspective économique, ce traitement offre un bon retour sur 
investissement pour les programmes de santé publique.
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Resumen
Costoeficacia del tratamiento preventivo intermitente (TPI) de la malaria en los lactantes (TPIL) en 
Mozambique y en la República Unida de Tanzanía
Objetivo Estimar la costoeficacia del tratamiento preventivo 
intermitente (TPI) de la malaria en los lactantes con sulfadoxina-
pirimetamina (SP).
Métodos En dos ensayos previos de TPI en lactantes llevados a cabo 
en Ifakara (República Unida de Tanzanía) y Manhiça (Mozambique), 
se administró SP en tres ocasiones a lactantes de menos de 9 meses 
a través del Programa Ampliado de Inmunización. A partir de los 
resultados sobre la eficacia de la intervención y de la incidencia de 
malaria en la población objetivo, se estimó el número de episodios 
clínicos de la enfermedad prevenidos. Esa cifra, unida a una tasa 
de letalidad supuesta del 1,57%, se usó a su vez para estimar el 
número de años de vida ajustados en función de la discapacidad 
(AVAD) evitados y el número de muertes evitadas. Por último, 
sobre la base de esas cifras se determinaron los costos iniciales y 
los costos ordinarios.
Resultados El costo por episodio clínico de malaria evitado fue 
de US$ 1,57 (intervalo: US$ 0,8–4,0) en Ifakara y de US$ 4,73 
(intervalo: US$ 1,7–30,3) en Manhiça; el costo por DALY evitado 
fue de US$ 3,7 (intervalo: US$ 1,6–12,2) en Ifakara y de US$ 11,2 
(intervalo: US$ 3,6–92,0) en Manhiça; y el costo por defunción 
evitada fue de US$ 100,2 (intervalo: US$ 43,0–330,9) en Ifakara 
y de US$ 301,1 (intervalo: US$ 95,6–2498,4) en Manhiça.
Conclusión Desde el punto de vista del sistema de salud y de la 
sociedad, cabe deducir que el TPI en lactantes con SP redunda en 
mejoras sanitarias de forma costoeficaz. Desde una perspectiva 
económica, la medida supone una buena inversión para los 
programas de salud pública.
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صخلم
ةدحتلما اينازنت ةيروهمج و قيبمزوم في عضرلا ىدل ايرلاملل ةعطقتلما ةيئاقولا ةجلاعلما ةيدودرم
 عضرلا  ىدل  ايرلاملل  ةعطقتلما  ةيئاقولا  ةجلاعلما  ةيدودرم  ريدقت  :فدهلا
.ينماثييميرب - ينسكودافلسلا لماعتساب
 ،عضرلا ىدل ايرلاملل ةعطقتلما ةيئاقولا ةجلاعملل ينتقباس ينتبرجت في :ةقيرطلا
 ،)قيبمزوبم(  ”اسيهنام”و  ،)ةدحتلما  اينازنت  ةيروهمجب(  ”اراكافيإ“  في  اتيرجأ
 رهشلا مهغولب لبق ،عضرلل تارم ثلاث ينماثييميرب – ينسكودافلسلا تيطعأ
 ةيلاعف جئاتن لىع ءانبو .عينمتلل عسولما جمانبرلا للاخ نم ،رمعلا نم عساتلا
 ددع ريدقت مت ،ةفدهتسلما ةيناكسلا ةعومجلما في ايرلالما تاعوقوو ،ةلخادلما
 بناج لىإ ددعلا اذه مدخُتساو .اهيقوت نكمأ يتلا ةيريسرلا ايرلالما تابون
 رمعلا  تاونس ددع ريدقتل  ،%1.57  هرادقم تلااحلا  ةتاملإ ضترفم لدعم
 تايفولا  ددع  كلذكو  ،اهبنجت  نكمأ  يتلا  ،زجعلا  ددم  باستحاب  ةححصلما
 ةيلولأا ءدبلا فيلاكت اهيف ابم ،ةلخادلما فيلاكت تردقو .اهيدافت نكمأ يتلا
.ماقرلأا هذه لىع ءانب ،ةرركتلما فيلاكتلاو
 رلاود 1.57 اهيقوت نكمأ ةيريسر ايرلام ةبون لك ةفلكت تغلب :تادوجولما
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 عضرلا  ىدل ايرلاملل ةعطقتلما  ةيئاقولا  ةجلاعلما يدؤت نأ عقوتي :جاتنتسلاا
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 في قفنت يتلا  لاوملأا نم ةميقلا  ةميظع ةدافتسا ةيمومعلا  ةحصلا جمابرل
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